Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriella Gobbi

Showing results (21-30 of 115) with videos related to

Pageof 12
Sort By:
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 17, 2009
Decline in serotonergic firing activity and desensitization of 5-HT1A autoreceptors after chronic unpredictable stressFrancis Rodriguez Bambico, Nhu-Tram Nguyen, Gabriella Gobbi
Journal of Clinical Psychopharmacology|February 28, 2012
The psychopharmacology of aggressive behavior: a translational approach: part 2: clinical studies using atypical antipsychotics, anticonvulsants, and lithiumStefano Comai, Michael Tau, Zoran Pavlovic, et al.
Frontiers in Pharmacology|February 18, 2022
Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum DisorderAthanasios Markopoulos, Antonio Inserra, Danilo De Gregorio, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 26, 2007
Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortexFrancis Rodriguez Bambico, Noam Katz, Guy Debonnel, et al.
Current Medicinal Chemistry|February 11, 2017
Targeting Melatonin MT2 Receptors: A Novel Pharmacological Avenue for Inflammatory and Neuropathic PainLuca Posa, Danilo De Gregorio, Gabriella Gobbi, et al.
International Journal of Molecular Sciences|November 26, 2016
d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and PharmacologyDanilo De Gregorio, Stefano Comai, Luca Posa, et al.
Journal of Clinical Psychopharmacology|November 4, 2021
Lifetime Cannabis Use Disorder Is Not Associated With Lifetime Impulsive Behavior and Severe Violence in Patients With Schizophrenia Spectrum Disorders From a High-Security HospitalStefano Comai, Yves Fuamba, Maria Chiara Rivolta, et al.
CNS Drugs|August 21, 2023
Lysergic Acid Diethylamide (LSD) for the Treatment of Anxiety Disorders: Preclinical and Clinical EvidenceAntonio Inserra, Alexandre Piot, Danilo De Gregorio, et al.
Journal of Clinical Psychopharmacology|June 27, 2003
Neurochemical and psychotropic effects of bupropion in healthy male subjectsGabriella Gobbi, Susan Slater, Nathalie Boucher, et al.
The International Journal of Neuropsychopharmacology|February 15, 2022
Sex Differences in Responses to Antidepressant Augmentations in Treatment-Resistant DepressionChristophe Moderie, Nicolas Nuñez, Allan Fielding, et al.
Pageof 12

Showing results (21-30 of 115) with videos related to

Sort By:
Pageof 12
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 17, 2009
Decline in serotonergic firing activity and desensitization of 5-HT1A autoreceptors after chronic unpredictable stressFrancis Rodriguez Bambico, Nhu-Tram Nguyen, Gabriella Gobbi
Journal of Clinical Psychopharmacology|February 28, 2012
The psychopharmacology of aggressive behavior: a translational approach: part 2: clinical studies using atypical antipsychotics, anticonvulsants, and lithiumStefano Comai, Michael Tau, Zoran Pavlovic, et al.
Frontiers in Pharmacology|February 18, 2022
Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum DisorderAthanasios Markopoulos, Antonio Inserra, Danilo De Gregorio, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 26, 2007
Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortexFrancis Rodriguez Bambico, Noam Katz, Guy Debonnel, et al.
Current Medicinal Chemistry|February 11, 2017
Targeting Melatonin MT2 Receptors: A Novel Pharmacological Avenue for Inflammatory and Neuropathic PainLuca Posa, Danilo De Gregorio, Gabriella Gobbi, et al.
International Journal of Molecular Sciences|November 26, 2016
d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and PharmacologyDanilo De Gregorio, Stefano Comai, Luca Posa, et al.
Journal of Clinical Psychopharmacology|November 4, 2021
Lifetime Cannabis Use Disorder Is Not Associated With Lifetime Impulsive Behavior and Severe Violence in Patients With Schizophrenia Spectrum Disorders From a High-Security HospitalStefano Comai, Yves Fuamba, Maria Chiara Rivolta, et al.
CNS Drugs|August 21, 2023
Lysergic Acid Diethylamide (LSD) for the Treatment of Anxiety Disorders: Preclinical and Clinical EvidenceAntonio Inserra, Alexandre Piot, Danilo De Gregorio, et al.
Journal of Clinical Psychopharmacology|June 27, 2003
Neurochemical and psychotropic effects of bupropion in healthy male subjectsGabriella Gobbi, Susan Slater, Nathalie Boucher, et al.
The International Journal of Neuropsychopharmacology|February 15, 2022
Sex Differences in Responses to Antidepressant Augmentations in Treatment-Resistant DepressionChristophe Moderie, Nicolas Nuñez, Allan Fielding, et al.
Pageof 12